Bevasiranib Uses, Dosage, Side Effects and more
Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
Bevasiranib represents the first drug in a promising new class of experimental medical treatments. It is a small interfering RNA (siRNA) drug, which silences the genes that produce Vascular Endothelial Growth Factor (VEGF), a protein that promotes blood vessel growth. The treatment slows the growth and leakage of abnormal blood vessels that are associated with the wet form of macular degeneration. The drug is injected directly into the eye.
| Trade Name | Bevasiranib |
| Generic | Bevasiranib |
| Bevasiranib Other Names | Bevasiranib |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in macular degeneration and diabetic retinopathy.
